Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway

Ma, Qiang; Pan, Weiqi; Li, Runfeng; Liu, Bin; Li, Chufang; Xie, Yuqi; Wang, Zhoulang; Zhao, Jin; Jiang, Haiming; Huang, Jicheng; Shi, Yongxia; Dai, Jun; Zheng, Kui; Li, Xiaobo; Yang, Zifeng

doi:10.1016/j.phrs.2020.104850

Cited by 115 publications

(95 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Through in silico study, they hypothesized that ACE2, 3CL protein as well as intracellular signaling composed of COX-2, CASP3, MAPK, arachidonic acid, HIF-1, NF-kB, and Ras are all potential targets of herbal medicines. Most recently Ma et al reported that Liu-Shen a herbal formulation exhibit favorable inhibitory effect against SARS-CoV-2 replication and virus-induced inflammation in vitro probably via suppressing NF-kB pathway (Ma et al, 2020).…”

Section: Herbal Medicines Alleviating Acute Respiratory Infectionmentioning

confidence: 99%

See 1 more Smart Citation

Current Prevention of COVID-19: Natural Products and Herbal Medicine

et al. 2020

View full text Add to dashboard Cite

Starting from December 2019, novel coronavirus disease 2019 (COVID-19) pandemic has caused tremendous economic loss and unprecedented health crisis across the globe. While the development of cure is at full speed, less attention and fewer effort have been spent on the prevention of this rapidly spreading respiratory infectious disease. Although so far, several vaccine candidates have advanced into clinical trials, limited data have been released regarding the vaccine efficacy and safety in human, not mention the long-term effectiveness of those vaccines remain as open question yet. Natural products and herbal medicines have been historically used for acute respiratory infection and generally show acceptable toxicity. The favorable stability for oral formulation and ease of scaling up manufacture make it ideal candidate for prophylactic. Hereby, we summarized the most recent advance in SARS-CoV-2 prevention including vaccine development as well as experimental prophylactics. Mainly, we reviewed the natural products showing inhibitory effect on human coronavirus, and discussed the herbal medicines lately used for COVID-19, especially focused on the herbal products already approved by regulatory agency with identifiable patent number. We demonstrated that to fill in the response gap between appropriate treatment and commercially available vaccine, repurposing natural products and herbal medicines as prophylactic will be a vigorous approach to stop or at least slow down SARS-CoV-2 transmission. In the interest of public health, this will lend health officials better control on the current pandemic.

show abstract

Section: Herbal Medicines Alleviating Acute Respiratory Infectionmentioning

confidence: 99%

“…Most recently Ma et al. reported that Liu-Shen a herbal formulation exhibit favorable inhibitory effect against SARS-CoV-2 replication and virus-induced inflammation in vitro probably via suppressing NF-κB pathway ( Ma et al., 2020 ).…”

Section: Herbal Medicines Alleviating Acute Respiratory Infectionmentioning

confidence: 99%

Current Prevention of COVID-19: Natural Products and Herbal Medicine

et al. 2020

View full text Add to dashboard Cite

show abstract

“…According to the recent findings, SARS-CoV-2 replication starts when the S (Spike) proteins attach to the membrane of the lung cells via angiotensin-converting enzyme 2 (ACE2) receptor, by the clathrin-dependent and -independent endocytosis, and release their RNA that senses by endosomal TLRs (TLR3, TLR7, TLR8, and TLR9), RIG-I, MDA5 and cGAS (nucleotidyltransferase cyclic GMP-AMP synthase) in the cytoplasm [ [24] , [25] , [26] ]. Interactions between SARS-CoV-2 and alveolar cells, trigger downstream signaling pathway via TIR-domain-containing adapter-inducing interferon-β (TRIF), and STING adaptor molecules lead to triggering MyD88 adaptor molecule, following that activation of the NF-κB and interferon regulatory factor 3 (IRF3) [ [27] , [28] , [29] ]. The result of this complex pathway is the production of IFN-α and -β and varied set of pro-inflammatory mediators.…”

Section: Introductionmentioning

confidence: 99%

The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19

et al. 2020

View full text Add to dashboard Cite

Aims The immune response is essential for the control and resolution of viral infections. Following the outbreak of novel coronavirus disease (COVID-19), several immunotherapies were applied to modulate the immune responses of the affected patients. In this review, we aimed to describe the role of the immune system in response to COVID-19. We also provide a systematic review to collate and describe all published reports of the using immunotherapies, including convalescent plasma therapy, monoclonal antibodies, cytokine therapy, mesenchymal stem cell therapy, and intravenous immunoglobulin and their important outcomes in COVID-19 patients. Material and methods A thorough search strategy was applied to identify published research trials in PubMed, Scopus, Medline, and EMBASE from Dec 1, 2019, to May 4, 2020, for studies reporting clinical outcomes of COVID-19 patients treated with immunotherapies along with other standard cares. Key findings From an initial screen of 80 identified studies, 24 studies provided clinical outcome data on the use of immunotherapies for the treatment of COVID-19 patients, including convalescent plasma therapy (33 patients), monoclonal antibodies (55 patients), interferon (31 patients), mesenchymal stem cell therapy (8 patient), and immunoglobulin (63 patients). Except for nine severe patients who died after treatment, most patients were recovered from COVID-19 with improved clinical symptoms and laboratory assessment. Significance Based on the available evidence, it seems that treatment with immunotherapy along with other standard cares could be an effective and safe approach to modulate the immune system and improvement of clinical outcomes.

show abstract

“…SARS-CoV-2 infection is mainly quantified by determining the number of infectious particles by counting virus-induced plaques or foci after staining with crystal violet, neutral red ( Keil et al, 2020 ; Ma et al, 2020 ; Runfeng et al, 2020 ; Xia et al, 2020a ) or specific antibodies for SARS-CoV-2 antigens, e.g. against the N protein ( Chu et al, 2020 ; Liu et al, 2020b ).…”

Section: Introductionmentioning

confidence: 99%

“…These antibodies are either labelled directly with horseradish peroxidase (HRP) or fluorophores, or are detected by a corresponding secondary labelled antibody. The number of infected cells is then detected by immunofluorescence microscopy, flow cytometry, or by manual counting by microscope or with the help of computational algorithms ( Liu et al, 2020a ; Ma et al, 2020 ; Ou et al, 2020 ; Runfeng et al, 2020 ). Other methods to quantify infection rates are detection of cell-associated RNA by RT-qPCR ( Monteil et al, 2020 ; Runfeng et al, 2020 ) or viral proteins by western blotting ( Ou et al, 2020 ), which are expensive and unsuitable for large sample numbers.…”

Section: Introductionmentioning

confidence: 99%

An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection

et al. 2020

View full text Add to dashboard Cite

SARS-CoV-2 is a novel pandemic coronavirus that caused a global health and economic crisis. The development of efficient drugs and vaccines against COVID-19 requires detailed knowledge about SARS-CoV-2 biology. Several techniques to detect SARS-CoV-2 infection have been established, mainly based on counting infected cells by staining plaques or foci, or by quantifying the viral genome by PCR. These methods are laborious, time-consuming and expensive and therefore not suitable for a high sample throughput or rapid diagnostics. We here report a novel enzyme-based immunodetection assay that directly quantifies the amount of de novo synthesized viral spike protein within fixed and permeabilized cells. This in-cell ELISA enables a rapid and quantitative detection of SARS-CoV-2 infection in microtiter format, regardless of the virus isolate or target cell culture. It follows the established method of performing ELISA assays and does not require expensive instrumentation. Utilization of the in-cell ELISA allows to e.g. determine TCID 50 of virus stocks, antiviral efficiencies (IC 50 values) of drugs or neutralizing activity of sera. Thus, the in-cell spike ELISA represents a promising alternative to study SARS-CoV-2 infection and inhibition and may facilitate future research.

show abstract

Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway

Cited by 115 publications

References 33 publications

Current Prevention of COVID-19: Natural Products and Herbal Medicine

Current Prevention of COVID-19: Natural Products and Herbal Medicine

The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19

An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection

Contact Info

Product

Resources

About